

Shaojun Zhang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/363974/publications.pdf>

Version: 2024-02-01

33
papers

4,269
citations

516710

16
h-index

501196

28
g-index

36
all docs

36
docs citations

36
times ranked

8538
citing authors

#	ARTICLE	IF	CITATIONS
1	Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib. American Journal of Hematology, 2021, 96, E137-E140.	4.1	6
2	Computational immune infiltration analysis of pediatric high-grade gliomas (pHGGs) reveals differences in immunosuppression and prognosis by tumor location. Computational and Systems Oncology, 2021, 1, e1016.	1.5	5
3	Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma. Nature Communications, 2021, 12, 2877.	12.8	35
4	Epithelial memory of inflammation limits tissue damage while promoting pancreatic tumorigenesis. Science, 2021, 373, eabj0486.	12.6	99
5	9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy. Nature Communications, 2021, 12, 5606.	12.8	76
6	Single-cell dissection of intratumoral heterogeneity and lineage diversity in metastatic gastric adenocarcinoma. Nature Medicine, 2021, 27, 141-151.	30.7	134
7	Integrated genomic profiling and modelling for risk stratification in patients with advanced oesophago-gastric adenocarcinoma. Gut, 2021, 70, 2055-2065.	12.1	24
8	Multiplex profiling of peritoneal metastases from gastric adenocarcinoma identified novel targets and molecular subtypes that predict treatment response. Gut, 2020, 69, 18-31.	12.1	94
9	Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nature Medicine, 2020, 26, 1878-1887.	30.7	321
10	B cells and tertiary lymphoid structures promote immunotherapy response. Nature, 2020, 577, 549-555.	27.8	1,421
11	Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) -outcomes and mutation profile from venetoclax resistant MCL patients. American Journal of Hematology, 2020, 95, 623-629.	4.1	54
12	Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL. Blood Advances, 2020, 4, 1038-1050.	5.2	43
13	Outcomes of Acalabrutinib Failures in Relapsed Mantle Cell Lymphoma. Blood, 2020, 136, 9-10.	1.4	2
14	Oncogenic MALT1 Promotes Cell Survival and Mediates Ibrutinib Resistance and Ibrutinib-Venetoclax Resistance in Mantle Cell Lymphoma. Blood, 2020, 136, 18-18.	1.4	2
15	Xeno-MCL: Genomic, Transcriptomic and Pathologic Landscape Associated with Disease Progression, Clonal Evolution and Tissue Tropism in Patient-Derived Xenografts of Mantle Cell Lymphoma. Blood, 2020, 136, 20-20.	1.4	0
16	Single Cell Transcriptomic Evolution and Resistance Mechanisms of BTK and BCL-2 Inhibition in Mantle Cell Lymphoma. Blood, 2020, 136, 33-34.	1.4	0
17	Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma. Science Translational Medicine, 2019, 11, .	12.4	161
18	Poor Response to Neoadjuvant Chemotherapy Correlates with Mast Cell Infiltration in Inflammatory Breast Cancer. Cancer Immunology Research, 2019, 7, 1025-1035.	3.4	70

#	ARTICLE	IF	CITATIONS
19	Integrated transcriptomic “genomic tool Texomer profiles cancer tissues. Nature Methods, 2019, 16, 401-404.	19.0	7
20	A pilot study of pembrolizumab in smoldering myeloma: report of the clinical, immune, and genomic analysis. Blood Advances, 2019, 3, 2400-2408.	5.2	28
21	Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age ≥ 65 years) with Mantle Cell Lymphoma (MCL) - Results of Phase-II Window-1 Clinical Trial. Blood, 2019, 134, 3987-3987.	1.4	12
22	Targeting PI3K and PLK1 to Overcome Ibrutinib-Venetoclax Resistance in Mantle Cell Lymphoma. Blood, 2019, 134, 4062-4062.	1.4	6
23	Analysis of Factors Predictive of Risk of Transformation and Time to Transformation in Patients (pts) with Mantle Cell Lymphoma - Cohort Study of 369 Patients. Blood, 2019, 134, 1526-1526.	1.4	0
24	Pdxd Models Empower Preclinical Drug Evaluation and Mechanistic Studies Via Faithful Recapitulation of the Pathology, Complex Heterogeneity, Genetic-Transcriptomic Landscape, and Therapeutic Response of Mantle Cell Lymphoma. Blood, 2019, 134, 3974-3974.	1.4	0
25	Genetically Defined Metabolic Targets Overcome Ibrutinib Resistance in Mantle Cell Lymphoma. Blood, 2019, 134, 395-395.	1.4	8
26	Transcriptomic Heterogeneity and Clonal Evolution Associated with Therapeutic Resistance in Mantle Cell Lymphoma Revealed By Single Cell RNA-Seq. Blood, 2019, 134, 5217-5217.	1.4	0
27	Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas. Cell Reports, 2018, 23, 239-254.e6.	6.4	801
28	Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nature Medicine, 2018, 24, 1649-1654.	30.7	592
29	Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib. British Journal of Haematology, 2018, 183, 578-587.	2.5	81
30	Outcomes, Causes of Discontinuation and Mutation Profile of Patients with Mantle Cell Lymphoma Who Progressed on Acalabrutinib. Blood, 2018, 132, 4151-4151.	1.4	4
31	Clinical and Genomic Characteristics in De Novo Blastoid/Pleomorphic (dnMCL) and Transformed Blastoid/Pleomorphic (t-MCL) Mantle Cell Lymphoma (MCL) in the Ibrutinib Era: Comprehensive Analysis of 168 Patients. Blood, 2018, 132, 1599-1599.	1.4	2
32	Ibrutinib-Resistant Mantle Cell Lymphoma Undergoes Metabolic Reprogramming Towards Oxphos. Blood, 2018, 132, 41-41.	1.4	0
33	Unravelling the Heterogeneity of Mantle Cell Lymphoma Ecosystem By Single Cell RNA Sequencing. Blood, 2018, 132, 4118-4118.	1.4	0